Denmark-based Bavarian Nordic A/S announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) exercised the first options under an existing contract to supply a freeze-dried version of the JYNNEOS® smallpox vaccine. The first doses of this vaccine version will be manufactured and invoiced in 2023 and 2024. If exercised, additional options on the BARDA contract support the conversion of up to a total of approximately 13 million freeze-dried doses of JYNNEOS smallpox vaccine that are expected to be manufactured in 2024 and 2025. The majority of the bulk vaccine for these doses has already been manufactured. A...